ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dose modification and management of alpelisib for rash and severe cutaneous adverse reactions

Dose modification and management of alpelisib for rash and severe cutaneous adverse reactions
Grade* RecommendationΔ

Grade 1

(<10% BSA with active skin toxicity)
  • No alpelisib dose adjustment required.
  • Initiate topical corticosteroid treatment.
  • Consider adding oral antihistamine to manage symptoms.
  • If active rash is not improved within 28 days of appropriate treatment, add a low-dose systemic corticosteroid.
  • If the etiology is SCAR, permanently discontinue alpelisib.

Grade 2

(10 to 30% BSA with active skin toxicity)
  • No alpelisib dose adjustment required.
  • Initiate or intensify topical corticosteroid and oral antihistamine treatment.
  • Consider low-dose systemic corticosteroid treatment.
  • If rash improves to grade ≤1 within 10 days, systemic corticosteroid may be discontinued.
  • If the etiology is SCAR, permanently discontinue alpelisib.

Grade 3 (eg, severe rash not responsive to medical management)

(>30% BSA with active skin toxicity)
  • Interrupt alpelisib.
  • Initiate or intensify topical/systemic corticosteroid and oral antihistamine treatment.
  • If the etiology is SCAR, permanently discontinue alpelisib.
  • If the etiology is not a SCAR, interrupt dose until improvement to grade ≤1, then resume alpelisib at next lower dose level.

Grade 4 (eg, severe bullous, blistering, or exfoliating skin conditions)

(any % BSA associated with extensive superinfection, with IV antibiotics indicated; life-threatening consequences)
  • Permanently discontinue alpelisib.
SCARs: severe cutaneous adverse reactions; BSA: body surface area; CTCAE: Common Terminology Criteria for Adverse Events.
* Grading according to CTCAE Version 5.0.
¶ For all grades of rash, consider consultation with a dermatologist.
Δ Antihistamines administered prior to rash onset may decrease incidence and severity of rash based on the SOLAR-1 trial.
Reproduced from: Alpelisib tablets. United States Prescribing Information. US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212526Orig1s004lbl.pdf (Accessed on July 23, 2021).
Graphic 132329 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟